Categories: Other
Description:
Brachytherapy can be used in high-risk prostate cancer, but not as monotherapy—it is typically part of a combined treatment approach with external beam radiation therapy (EBRT) and long-term androgen deprivation therapy (ADT). This strategy, known as trimodal therapy, is used to intensify local treatment in patients with aggressive disease.
In this setting, brachytherapy boosts the total radiation dose delivered to the prostate, improving cancer control compared to EBRT alone. It is most suitable for patients with good urinary function, smaller prostate size, and who can tolerate a more aggressive regimen. However, due to higher toxicity risks—particularly urinary side effects—it requires careful patient selection and experienced providers.
Treatment For:
AI generated Summary: Based on the provided information, there are no user reviews available for the effectiveness of Brachytherapy as a treatment for High Risk Prostate Cancer. The author has not provided any review or rating, making it difficult to determine the efficacy of this treatment without additional data or evidence from clinical studies or expert opinions.
The information, including but not limited to, text, graphics, images and other material contained on this website/app are for informational purposes only. No material on this site/app is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website/app.
Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.
